Literature DB >> 27628491

Intensity-Modulated Radiation Therapy May Improve Local-Regional Tumor Control for Locally Advanced Non-Small Cell Lung Cancer Compared With Three-Dimensional Conformal Radiation Therapy.

Jingbo Wang1, Zongmei Zhou1, Jun Liang1, Qinfu Feng1, Zefen Xiao1, Zhouguang Hui1, Xiaozhen Wang1, Jima Lv1, Dongfu Chen1, Hongxing Zhang1, Zhe Ji1, Jianzhong Cao1, Lipin Liu1, Wei Jiang1, Yu Men1, Cai Xu1, Jiangrong Dai1, Weibo Yin1, Luhua Wang2.   

Abstract

BACKGROUND: Consistent results are lacking as regards the comparative effectiveness of intensity-modulated radiotherapy (IMRT) versus three-dimensional conformal radiotherapy (3DCRT) in patients with locally advanced non-small cell lung cancer (LA-NSCLC). PATIENTS AND METHODS: Patients treated with definitive radiotherapy (RT) between 2002 and 2010 were retrospectively reviewed. Overall survival (OS), local-regional progression-free survival (LRPFS), distant metastasis-free survival (DMFS), and progression-free survival (PFS) were compared among patients irradiated with different techniques. The association between RT technique and survival indexes was assessed in a Cox proportional hazard regression model. Propensity score matching (PSM) was used to balance known confounding factors.
RESULTS: A total of 652 patients were eligible for analysis, including 206 with 3DCRT and 446 with IMRT. The median OS of the 3DCRT and IMRT groups were 19.4 and 23.3 months, with the 5-year rate of 13% and 19%, respectively (p = .043). Multivariate analysis identified IMRT as an independent favorable factor associated with LRPFS and DMFS. PSM analysis further verified the beneficial effect of IMRT on LRPFS. No difference in OS or PFS was observed between the two techniques. Subgroup analysis revealed that IMRT might be differentially more effective in both OS and LRPFS among patients who were female, nonsmokers, with adenocarcinoma, or without weight loss. There was a significant reduction of lung toxicity and similar esophagus toxicity in the IMRT group when compared with the 3DCRT group.
CONCLUSION: IMRT may confer superior LRPFS and comparable OS than can be achieved with 3DCRT in LA-NSCLC, along with the reduction of pulmonary toxicity. IMPLICATIONS FOR PRACTICE: Based on the largest number of patients from a single institution, the present study demonstrated that intensity-modulated radiotherapy (IMRT) could provide superior local-regional progression-free survival and similar overall survival compared with the traditional three-dimensional conformal radiotherapy (3DCRT) for stage III non-small cell lung cancer (NSCLC). IMRT was also found to be associated with the significantly decreased incidence of pulmonary toxicity. These results suggest that IMRT should be considered a surrogate for 3DCRT in locally advanced NSCLC and might be the preferred option for a female nonsmoker with adenocarcinoma and a potentially high risk of pulmonary toxicity from radiotherapy. ©AlphaMed Press.

Entities:  

Keywords:  Intensity-modulated radiation therapy; Non-small cell lung cancer; Survival; Three-dimensional conformal radiation therapy; Toxicity

Mesh:

Year:  2016        PMID: 27628491      PMCID: PMC5153339          DOI: 10.1634/theoncologist.2016-0155

Source DB:  PubMed          Journal:  Oncologist        ISSN: 1083-7159


  20 in total

1.  Long-term clinical outcome of intensity-modulated radiotherapy for inoperable non-small cell lung cancer: the MD Anderson experience.

Authors:  Zhi-Qin Jiang; Kunyu Yang; Ritsuko Komaki; Xiong Wei; Susan L Tucker; Yan Zhuang; Mary K Martel; Sastray Vedam; Peter Balter; Guangying Zhu; Daniel Gomez; Charles Lu; Radhe Mohan; James D Cox; Zhongxing Liao
Journal:  Int J Radiat Oncol Biol Phys       Date:  2011-11-11       Impact factor: 7.038

2.  Comparison of outcomes for patients with medically inoperable Stage I non-small-cell lung cancer treated with two-dimensional vs. three-dimensional radiotherapy.

Authors:  L Christine Fang; Ritsuko Komaki; Pamela Allen; Thomas Guerrero; Radhe Mohan; James D Cox
Journal:  Int J Radiat Oncol Biol Phys       Date:  2006-09-01       Impact factor: 7.038

3.  Initial evaluation of treatment-related pneumonitis in advanced-stage non-small-cell lung cancer patients treated with concurrent chemotherapy and intensity-modulated radiotherapy.

Authors:  Sue S Yom; Zhongxing Liao; H Helen Liu; Susan L Tucker; Chao-Su Hu; Xiong Wei; Xuanming Wang; Shulian Wang; Radhe Mohan; James D Cox; Ritsuko Komaki
Journal:  Int J Radiat Oncol Biol Phys       Date:  2007-02-22       Impact factor: 7.038

4.  Recursive partitioning analysis of 1999 Radiation Therapy Oncology Group (RTOG) patients with locally-advanced non-small-cell lung cancer (LA-NSCLC): identification of five groups with different survival.

Authors:  M Werner-Wasik; C Scott; J D Cox; W T Sause; R W Byhardt; S Asbell; A Russell; R Komaki; J S Lee
Journal:  Int J Radiat Oncol Biol Phys       Date:  2000-12-01       Impact factor: 7.038

5.  [Therapeutic efficacy of three-dimensional conformal radiation therapy for patients with locally advanced non-small cell lung cancer].

Authors:  Jian-zhong Cao; Guang-fei Ou; Jun Liang; Ji-ma Lü; Zong-mei Zhou; Dong-fu Chen; Ze-fen Xiao; Qin-fu Feng; Hong-xing Zhang; Lü-hua Wang; Wei-bo Yin
Journal:  Zhonghua Zhong Liu Za Zhi       Date:  2011-07

6.  Influence of technologic advances on outcomes in patients with unresectable, locally advanced non-small-cell lung cancer receiving concomitant chemoradiotherapy.

Authors:  Zhongxing X Liao; Ritsuko R Komaki; Howard D Thames; Helen H Liu; Susan L Tucker; Radhe Mohan; Mary K Martel; Xiong Wei; Kunyu Yang; Edward S Kim; George Blumenschein; Waun Ki Hong; James D Cox
Journal:  Int J Radiat Oncol Biol Phys       Date:  2009-06-08       Impact factor: 7.038

7.  Feasibility of sparing lung and other thoracic structures with intensity-modulated radiotherapy for non-small-cell lung cancer.

Authors:  H Helen Liu; Xiaochun Wang; Lei Dong; Qiuwen Wu; Zhongxing Liao; Craig W Stevens; Thomas M Guerrero; Ritsuko Komaki; James D Cox; Radhe Mohan
Journal:  Int J Radiat Oncol Biol Phys       Date:  2004-03-15       Impact factor: 7.038

8.  A population-based comparative effectiveness study of radiation therapy techniques in stage III non-small cell lung cancer.

Authors:  Jeremy P Harris; James D Murphy; Alexandra L Hanlon; Quynh-Thu Le; Billy W Loo; Maximilian Diehn
Journal:  Int J Radiat Oncol Biol Phys       Date:  2014-02-01       Impact factor: 7.038

9.  Cancer risks attributable to low doses of ionizing radiation: assessing what we really know.

Authors:  David J Brenner; Richard Doll; Dudley T Goodhead; Eric J Hall; Charles E Land; John B Little; Jay H Lubin; Dale L Preston; R Julian Preston; Jerome S Puskin; Elaine Ron; Rainer K Sachs; Jonathan M Samet; Richard B Setlow; Marco Zaider
Journal:  Proc Natl Acad Sci U S A       Date:  2003-11-10       Impact factor: 11.205

10.  Influence of conformal radiotherapy technique on survival after chemoradiotherapy for patients with stage III non-small cell lung cancer in the National Cancer Data Base.

Authors:  David J Sher; Matthew Koshy; Michael J Liptay; Mary Jo Fidler
Journal:  Cancer       Date:  2014-04-01       Impact factor: 6.860

View more
  15 in total

1.  Postoperative Radiotherapy for Resected Stage IIIA-N2 Non-small-cell Lung Cancer: A Population-Based Time-Trend Study.

Authors:  Wan-Qin Zeng; Wen Feng; Li Xie; Chen-Chen Zhang; Wen Yu; Xu-Wei Cai; Xiao-Long Fu
Journal:  Lung       Date:  2019-11-08       Impact factor: 2.584

2.  Impact of modern radiotherapy techniques on survival outcomes for unselected patients with large volume non-small cell lung cancer.

Authors:  Raj Kumar Shrimali; Santam Chakraborty; Sriram Prasath; B Arun; Sanjoy Chatterjee
Journal:  Br J Radiol       Date:  2018-11-29       Impact factor: 3.039

Review 3.  Advanced radiation techniques for locally advanced non-small cell lung cancer: intensity-modulated radiation therapy and proton therapy.

Authors:  Nikhil Yegya-Raman; Wei Zou; Ke Nie; Jyoti Malhotra; Salma K Jabbour
Journal:  J Thorac Dis       Date:  2018-08       Impact factor: 2.895

4.  Surgical complications and clinical outcomes after dose-escalated trimodality therapy for non-small cell lung cancer in the era of intensity-modulated radiotherapy.

Authors:  Kevin X Liu; Kailan Sierra-Davidson; Kevin Tyan; Lawrence T Orlina; J Paul Marcoux; Benjamin H Kann; David E Kozono; Raymond H Mak; Abby White; Lisa Singer
Journal:  Radiother Oncol       Date:  2021-10-22       Impact factor: 6.280

5.  Increased CYFRA 21-1, CEA and NSE are Prognostic of Poor Outcome for Locally Advanced Squamous Cell Carcinoma in Lung: A Nomogram and Recursive Partitioning Risk Stratification Analysis.

Authors:  Jingbo Wang; Wei Jiang; Tao Zhang; Lipin Liu; Nan Bi; Xiaozhen Wang; Zhouguang Hui; Jun Liang; Jima Lv; Zongmei Zhou; Zefen Xiao; Qinfu Feng; Dongfu Chen; Weibo Yin; Luhua Wang
Journal:  Transl Oncol       Date:  2018-06-27       Impact factor: 4.243

6.  Comparison of efficacy and safety between simultaneous integrated boost intensity-modulated radiotherapy and conventional intensity-modulated radiotherapy in locally advanced non-small-cell lung cancer: a retrospective study.

Authors:  Daquan Wang; Nan Bi; Tao Zhang; Zongmei Zhou; Zefen Xiao; Jun Liang; Dongfu Chen; Zhouguang Hui; Jima Lv; Xiaozhen Wang; Xin Wang; Lei Deng; Wenqing Wang; Jingbo Wang; Chunyu Wang; Xiaotong Lu; Kunpeng Xu; Linfang Wu; Wenji Xue; Qinfu Feng; Luhua Wang
Journal:  Radiat Oncol       Date:  2019-06-13       Impact factor: 3.481

7.  Efficacy and safety of concurrent chemoradiotherapy in ECOG 2 patients with locally advanced non-small-cell lung cancer: a subgroup analysis of a randomized phase III trial.

Authors:  Nan Bi; Lipin Liu; Jun Liang; Shixiu Wu; Ming Chen; Changxing Lv; Lujun Zhao; Anhui Shi; Wei Jiang; Yaping Xu; Zongmei Zhou; Jingbo Wang; Wenqing Wang; Dongfu Chen; Zhouguang Hui; Jima Lv; Hongxing Zhang; Qinfu Feng; Zefen Xiao; Xin Wang; Tao Zhang; Weibo Yin; Junling Li; Jie He; Luhua Wang
Journal:  BMC Cancer       Date:  2020-04-06       Impact factor: 4.430

8.  Application of intensity-modulated radiation therapy in the treatment of nasopharyngeal carcinoma.

Authors:  Hao Yan; Xiaoming Cao; Jinmei Wang
Journal:  Oncol Lett       Date:  2017-10-16       Impact factor: 2.967

9.  Selective ATP hydrolysis inhibition in F1Fo ATP synthase enhances radiosensitivity in non-small-cell lung cancer cells (A549).

Authors:  Yupei Wang; Qinzheng Hou; Guoqing Xiao; Shifeng Yang; Cuixia Di; Jing Si; Rong Zhou; Yancheng Ye; Yanshan Zhang; Hong Zhang
Journal:  Oncotarget       Date:  2017-06-27

10.  Is clinical target volume necessary?-a failure pattern analysis in patients with locally advanced non-small cell lung cancer treated with concurrent chemoradiotherapy using intensity-modulated radiotherapy technique.

Authors:  Liqing Zou; Li Chu; Fan Xia; Lijun Zhou; Xi Yang; Jianjiao Ni; Junchao Chen; Zhengfei Zhu
Journal:  Transl Lung Cancer Res       Date:  2020-10
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.